Posted by Michael Wonder on 11 Oct 2019
MSF demands Johnson & Johnson reduce price of life saving TB drug
11 October 2019 - Pharma company Johnson and Johnson sell TB drug bedaquiline for nearly US$1,200 per treatment course, a price that is out of reach for many who need it.
Médecins Sans Frontières (MSF) has launched a global campaign calling on pharmaceutical corporation Johnson & Johnson (J&J) to lower the price of its anti-tuberculosis medicine bedaquiline to no more than US$1 per day for people everywhere who need it, in order to allow scale-up of drug-resistant tuberculosis (DR-TB) treatment and reduce deaths.
We are demanding this price cut considering the joint contributions made in the development of this drug, including our own contribution. MSF was joined by TB activists and civil society in protests outside of J&J offices in the US, South Africa, Brazil, Belgium, Ukraine and Spain demanding the corporation make the drug available for people with DR-TB for no more than ‘a dollar a day’.
